Treatments
TL;DR: 10 FDA-approved drugs have labels that mention cervical cancer in their indications. Grouped below by mechanism of action. This list gives you the vocabulary — your oncologist chooses a regimen based on your specific subtype, stage, biomarkers, and prior therapies.
Source: OpenFDA drug label API · last checked
Cost transparency
Drugs below have published Medicare Part B or Part D spending figures — what the federal government actually paid per beneficiary in 2023.
Figures are average Medicare spending per beneficiary. Out-of-pocket varies by insurance and manufacturer assistance. See all drug costs →
Drugs that activate or modify the immune system to attack cancer cells. Checkpoint inhibitors (targeting PD-1, PD-L1, CTLA-4) are the most common.
Programmed Death Receptor-1 Blocking Antibody [EPC] · Programmed Death Receptor-1-directed Antibody Interactions [MoA]
From the FDA label: 1 INDICATIONS AND USAGE KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma for the treatment of patients with unresectable or metastatic melanoma. ( 1.1 ) for the adjuvant treatment of adult and pediatric…
Endoglycosidase [EPC] · Programmed Death Receptor-1 Blocking Antibody [EPC]
From the FDA label: 1 INDICATIONS AND USAGE KEYTRUDA QLEX is a combination of pembrolizumab, a programmed death receptor-1 (PD-1)-blocking antibody, and berahyaluronidase alfa, an endoglycosidase, indicated: Melanoma for the treatment of adult patients with un…
Monoclonal antibodies and antibody-drug conjugates (ADCs) that bind specific proteins on cancer cells.
Vascular Endothelial Growth Factor Inhibitor [EPC] · Vascular Endothelial Growth Factor-directed Antibody Interactions [MoA]
From the FDA label: 1 INDICATIONS AND USAGE Avastin is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatm…
Vascular Endothelial Growth Factor Inhibitor [EPC] · Vascular Endothelial Growth Factor-directed Antibody Interactions [MoA]
From the FDA label: 1 INDICATIONS AND USAGE VEGZELMA is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treat…
Vascular Endothelial Growth Factor Inhibitor [EPC] · Vascular Endothelial Growth Factor-directed Antibody Interactions [MoA]
From the FDA label: 1 INDICATIONS AND USAGE MVASI is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatmen…
Vascular Endothelial Growth Factor Inhibitor [EPC] · Vascular Endothelial Growth Factor-directed Antibody Interactions [MoA]
From the FDA label: 1 INDICATIONS AND USAGE ZIRABEV is a vascular endothelial growth factor inhibitor indicated for the treatment of: • Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line trea…
From the FDA label: 1 INDICATIONS AND USAGE Alymsys is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatm…
Vascular Endothelial Growth Factor Inhibitor [EPC] · Vascular Endothelial Growth Factor-directed Antibody Interactions [MoA]
From the FDA label: 1 INDICATIONS AND USAGE Jobevne is a vascular endothelial growth factor inhibitor indicated for the treatment of: • Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first-or second-line treat…
From the FDA label: 1 INDICATIONS AND USAGE TIVDAK ® is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. TIVDAK is a tissue factor-directed antibody and microtubule in…
Cytotoxic drugs that kill rapidly dividing cells. Includes platinums, taxanes, antimetabolites, alkylators, topoisomerase inhibitors, and anthracyclines.
From the FDA label: 1 INDICATIONS AND USAGE Topotecan Hydrochloride for injection is a topoisomerase inhibitor indicated for treatment of: Patients with metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy, as a si…
Disease foundations below have active funds covering cervical cancer medications. Manufacturer patient-assistance programs are listed on each drug's cost page.
copay, premium, and deductible assistance for insured patients; fund availability varies by disease
https://www.healthwellfoundation.org/disease-funds/Funds open and close based on availability; check disease-funds page for current status
copay assistance for 20+ cancer types via disease-specific funds
https://www.panfoundation.org/find-disease-fund/Merging with Patient Advocate Foundation; unified 'TotalAssist' program launches 2026-07-01
case management, insurance appeals, legal counseling for patients with chronic or life-threatening illness
https://www.patientadvocate.org/Merging with PAN Foundation; launching 'TotalAssist' 2026-07-01
Trials test new therapies before they are FDA-approved. Often a way to access tomorrow's drugs today.
Back to Cervical Cancer hub →Stats, second opinions, NCI cancer centers, oncologists.
Understand biomarkers →Most targeted therapies require biomarker testing. Here's what you need to know.
Read your pathology report →Which drugs apply to you depends on what's in your pathology.